{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:36:04Z","timestamp":1791920164063,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T00:00:00Z","timestamp":1430956800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12967-015-0511-3","type":"journal-article","created":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T09:08:37Z","timestamp":1430903317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer"],"prefix":"10.1186","volume":"13","author":[{"given":"Dirk O","family":"Bauerschlag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Maass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Leonhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik A","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Pecks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Zeppernick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Morgenroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix M","family":"Mottaghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Tolba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Meinhold-Heerlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Br\u00e4utigam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,7]]},"reference":[{"key":"511_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1517\/14656566.2.1.109","volume":"2","author":"GH Eltabbakh","year":"2001","unstructured":"Eltabbakh GH, Awtrey CS. Current treatment for ovarian cancer. Expert Opin Pharmacother. 2001;2:109\u201324.","journal-title":"Expert Opin Pharmacother"},{"key":"511_CR2","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"511_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3322\/caac.20113","volume":"61","author":"D Jelovac","year":"2011","unstructured":"Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:183\u2013203.","journal-title":"CA Cancer J Clin"},{"key":"511_CR4","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1073\/pnas.97.7.3450","volume":"97","author":"FP Kuhajda","year":"2000","unstructured":"Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A. 2000;97:3450\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"511_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0899-9007(99)00266-X","volume":"16","author":"FP Kuhajda","year":"2000","unstructured":"Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000;16:202\u20138.","journal-title":"Nutrition"},{"key":"511_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2119\/molmed.2011.00046","volume":"17","author":"S Uddin","year":"2011","unstructured":"Uddin S, Jehan Z, Ahmed M, Alyan A, Al-Dayel F, Hussain A, et al. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis. Mol Med. 2011;17:635\u201345.","journal-title":"Mol Med"},{"key":"511_CR7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/sj.onc.1208298","volume":"24","author":"I Meinhold-Heerlein","year":"2005","unstructured":"Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene. 2005;24:1053\u201365.","journal-title":"Oncogene"},{"key":"511_CR8","first-page":"151","volume":"27","author":"RJ Kurman","year":"2008","unstructured":"Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27:151\u201360.","journal-title":"Int J Gynecol Pathol"},{"key":"511_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","volume":"460","author":"J Prat","year":"2012","unstructured":"Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237\u201349.","journal-title":"Virchows Arch"},{"key":"511_CR10","first-page":"707","volume":"1","author":"S Rossi","year":"2003","unstructured":"Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003;1:707\u201315.","journal-title":"Mol Cancer Res"},{"key":"511_CR11","first-page":"2204","volume":"9","author":"T Takahiro","year":"2003","unstructured":"Takahiro T, Shinichi K, Toshimitsu S. Expression of fatty acid synthase as a prognostic indicator in soft tissue sarcomas. Clin Cancer Res. 2003;9:2204\u201312.","journal-title":"Clin Cancer Res"},{"key":"511_CR12","first-page":"1081","volume":"18","author":"JA Menendez","year":"2006","unstructured":"Menendez JA, Vellon L, Lupu R. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2\/neu and TOP2A genes. Int J Mol Med. 2006;18:1081\u20137.","journal-title":"Int J Mol Med"},{"key":"511_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061524","volume":"8","author":"AS Meena","year":"2013","unstructured":"Meena AS, Sharma A, Kumari R, Mohammad N, Singh SV, Bhat MK. Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved. PLoS One. 2013;8, e61524.","journal-title":"PLoS One"},{"key":"511_CR14","doi-asserted-by":"publisher","first-page":"285191","DOI":"10.1155\/2010\/285191","volume":"2010","author":"SM Ueda","year":"2010","unstructured":"Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wang TL, et al. Expression of fatty acid synthase depends on nac1 and is associated with recurrent ovarian serous carcinomas. J Oncol. 2010;2010:285191.","journal-title":"J Oncol"},{"key":"511_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433\u201343.","journal-title":"Am J Surg Pathol"},{"key":"511_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0002-9440(10)64084-9","volume":"158","author":"I Meinhold-Heerlein","year":"2001","unstructured":"Meinhold-Heerlein I, Stenner-Liewen F, Liewen H, Kitada S, Krajewska M, Krajewski S, et al. Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer. Am J Pathol. 2001;158:1335\u201344.","journal-title":"Am J Pathol"},{"key":"511_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00432-010-0952-2","volume":"137","author":"K Brautigam","year":"2011","unstructured":"Brautigam K, Biernath-Wupping J, Bauerschlag DO, von Kaisenberg CS, Jonat W, Maass N, et al. Combined treatment with TRAIL and PPARgamma ligands overcomes chemoresistance of ovarian cancer cell lines. J Cancer Res Clin Oncol. 2011;137:875\u201386.","journal-title":"J Cancer Res Clin Oncol"},{"key":"511_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1593\/tlo.09121","volume":"2","author":"K Brautigam","year":"2009","unstructured":"Brautigam K, Bauerschlag DO, Weigel MT, Biernath-Wupping J, Bauknecht T, Arnold N, et al. Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1\/2 phosphorylation. Transl Oncol. 2009;2:164\u201373.","journal-title":"Transl Oncol"},{"key":"511_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4103\/0377-4929.97849","volume":"55","author":"ZL Liu","year":"2012","unstructured":"Liu ZL, Zhou Y, Luo QF, Hu M, Wang G, Huang SH, et al. Inhibition of fatty acid synthase supresses osteosarcoma cell invasion and migration. Indian J Pathol Microbiol. 2012;55:163\u20139.","journal-title":"Indian J Pathol Microbiol"},{"key":"511_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/labinvest.2010.157","volume":"91","author":"KG Zecchin","year":"2011","unstructured":"Zecchin KG, Rossato FA, Raposo HF, Melo DR, Alberici LC, Oliveira HC, et al. Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis. Lab Invest. 2011;91:232\u201340.","journal-title":"Lab Invest"},{"key":"511_CR21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/neuonc\/noq004","volume":"12","author":"D Haase","year":"2010","unstructured":"Haase D, Schmidl S, Ewald C, Kalff R, Huebner C, Firsching R, et al. Fatty acid synthase as a novel target for meningioma therapy. Neuro Oncol. 2010;12:844\u201354.","journal-title":"Neuro Oncol"},{"key":"511_CR22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/oxfordjournals.jbchem.a122739","volume":"105","author":"H Funabashi","year":"1989","unstructured":"Funabashi H, Kawaguchi A, Tomoda H, Omura S, Okuda S, Iwasaki S. Binding site of cerulenin in fatty acid synthetase. J Biochem. 1989;105:751\u20135.","journal-title":"J Biochem"},{"key":"511_CR23","first-page":"2745","volume":"56","author":"ES Pizer","year":"1996","unstructured":"Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE, Kuhajda FP. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res. 1996;56:2745\u20137.","journal-title":"Cancer Res"},{"key":"511_CR24","first-page":"1189","volume":"56","author":"ES Pizer","year":"1996","unstructured":"Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 1996;56:1189\u201393.","journal-title":"Cancer Res"},{"key":"511_CR25","first-page":"213","volume":"60","author":"ES Pizer","year":"2000","unstructured":"Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 2000;60:213\u20138.","journal-title":"Cancer Res"},{"key":"511_CR26","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1038\/sj.onc.1207476","volume":"23","author":"JA Menendez","year":"2004","unstructured":"Menendez JA, Oza BP, Atlas E, Verma VA, Mehmi I, Lupu R. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Oncogene. 2004;23:4945\u201358.","journal-title":"Oncogene"},{"key":"511_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/pros.1052","volume":"47","author":"ES Pizer","year":"2001","unstructured":"Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate. 2001;47:102\u201310.","journal-title":"Prostate"},{"key":"511_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbrc.2009.05.085","volume":"385","author":"TW Grunt","year":"2009","unstructured":"Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, et al. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun. 2009;385:454\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"511_CR29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12032-014-0391-z","volume":"32","author":"Y Cai","year":"2015","unstructured":"Cai Y, Wang J, Zhang L, Wu D, Yu D, Tian X, et al. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer. Med Oncol. 2015;32:391.","journal-title":"Med Oncol"},{"key":"511_CR30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3892\/ijo.2013.1978","volume":"43","author":"R Shiragami","year":"2013","unstructured":"Shiragami R, Murata S, Kosugi C, Tezuka T, Yamazaki M, Hirano A, et al. Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells. Int J Oncol. 2013;43:431\u20138.","journal-title":"Int J Oncol"},{"key":"511_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/1471-2407-12-280","volume":"12","author":"J Relat","year":"2012","unstructured":"Relat J, Blancafort A, Oliveras G, Cufi S, Haro D, Marrero PF, et al. Different fatty acid metabolism effects of (\u2212)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer. BMC Cancer. 2012;12:280.","journal-title":"BMC Cancer"},{"key":"511_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/ijc.20754","volume":"115","author":"JA Menendez","year":"2005","unstructured":"Menendez JA, Vellon L, Colomer R, Lupu R. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int J Cancer. 2005;115:19\u201335.","journal-title":"Int J Cancer"},{"key":"511_CR33","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0022-2275(20)38490-X","volume":"29","author":"S Murthy","year":"1988","unstructured":"Murthy S, Albright E, Mathur SN, Field FJ. Modification of CaCo-2 cell membrane fatty acid composition by eicosapentaenoic acid and palmitic acid: effect on cholesterol metabolism. J Lipid Res. 1988;29:773\u201380.","journal-title":"J Lipid Res"},{"key":"511_CR34","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1073\/pnas.91.14.6379","volume":"91","author":"FP Kuhajda","year":"1994","unstructured":"Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A. 1994;91:6379\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"511_CR35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3892\/ol.2014.2159","volume":"8","author":"P Zhao","year":"2014","unstructured":"Zhao P, Mao JM, Zhang SY, Zhou ZQ, Tan Y, Zhang Y. Quercetin induces HepG2 cell apoptosis by inhibiting fatty acid biosynthesis. Oncol Lett. 2014;8:765\u20139.","journal-title":"Oncol Lett"},{"key":"511_CR36","first-page":"1051","volume":"44","author":"T Torizuka","year":"2003","unstructured":"Torizuka T, Kanno T, Futatsubashi M, Okada H, Yoshikawa E, Nakamura F, et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J Nucl Med. 2003;44:1051\u20136.","journal-title":"J Nucl Med"},{"key":"511_CR37","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383.","journal-title":"N Engl J Med"},{"key":"511_CR38","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302\u20138.","journal-title":"J Clin Oncol"},{"key":"511_CR39","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396.","journal-title":"N Engl J Med"},{"key":"511_CR40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.4161\/cbt.28557","volume":"15","author":"N Staropoli","year":"2014","unstructured":"Staropoli N, Ciliberto D, Botta C, Fiorillo L, Grimaldi A, Lama S, et al. Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials. Cancer Biol Ther. 2014;15:707\u201320.","journal-title":"Cancer Biol Ther"},{"key":"511_CR41","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11307-012-0587-6","volume":"15","author":"M Sankaranarayanapillai","year":"2013","unstructured":"Sankaranarayanapillai M, Zhang N, Baggerly KA, Gelovani JG. Metabolic shifts induced by fatty acid synthase inhibitor orlistat in non-small cell lung carcinoma cells provide novel pharmacodynamic biomarkers for positron emission tomography and magnetic resonance spectroscopy. Mol Imaging Biol. 2013;15:136\u201347.","journal-title":"Mol Imaging Biol"},{"key":"511_CR42","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1016\/j.bmcl.2008.06.091","volume":"18","author":"HS Hoover","year":"2008","unstructured":"Hoover HS, Blankman JL, Niessen S, Cravatt BF. Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. Bioorg Med Chem Lett. 2008;18:5838\u201341.","journal-title":"Bioorg Med Chem Lett"},{"key":"511_CR43","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1177\/009127009603601104","volume":"36","author":"J Zhi","year":"1996","unstructured":"Zhi J, Melia AT, Funk C, Viger-Chougnet A, Hopfgartner G, Lausecker B, et al. Metabolic profiles of minimally absorbed orlistat in obese\/overweight volunteers. J Clin Pharmacol. 1996;36:1006\u201311.","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-015-0511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-015-0511-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-015-0511-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-015-0511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T08:13:22Z","timestamp":1630570402000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-015-0511-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["511"],"URL":"https:\/\/doi.org\/10.1186\/s12967-015-0511-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,7]]},"assertion":[{"value":"19 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"146"}}